FDA Accepts BLA for Gazyva/Gazyvaro for Systemic Lupus Erythematosus

The FDA has accepted a (sBLA) from Roche for Gazyva/Gazyvaro (obinutuzumab) for the treatment of systemic lupus erythematosus (SLE), marking a potential step toward a new treatment option for the most common form of lupus.

The regulatory submission is supported by positive results from the Phase III ALLEGORY trial,¹ which demonstrated significant reductions in disease activity compared with placebo. A decision from the FDA is expected by December 2026.

What did the ALLEGORY trial show?

The randomized, double-blind, placebo-controlled Phase III ALLEGORY study evaluated obinutuzumab in approximately 300 patients with SLE receiving standard therapy.

At 52 weeks, 76.7% of patients treated with Gazyva/Gazyvaro plus standard

therapy achieved a four-point or greater improvement on the SLE Responder Index (SRI-4), compared with 53.5% in the placebo group. The treatment also met all key secondary endpoints, including improved composite disease assessments and reduced glucocorticoid use.²

Notably, patients receiving Gazyva/Gazyvaro experienced fewer disease flares and more than double the remission rate compared with placebo. Safety findings were consistent with the drug’s established profile, with no new safety signals identified.

Why is this filing significant for lupus treatment?

SLE is a chronic, potentially life-threatening autoimmune disease affecting more than three million people worldwide. It is characterized by inflammation across multiple organ systems, including the skin, joints, and kidneys, and is associated with recurrent flares that can lead to irreversible organ damage.

If approved, Gazyva/Gazyvaro would be the first anti-CD20 therapy specifically targeting B cells in SLE, potentially establishing a new standard of care in a disease area with ongoing unmet need.

How does obinutuzumab work?

Obinutuzumab is a humanized monoclonal antibody designed to target CD20, a protein expressed on certain B cells. By directly inducing B cell death and enhancing antibody-dependent cellular cytotoxicity, the therapy aims to reduce the immune system activity that drives lupus disease progression.

The CD20-directed cytolytic antibody is currently approved in more than 100 countries for the treatment of lymphoma, including in combination with chlorambucil for the treatment of patients with previously untreated chronic lymphocytic leukemia; in combination with chemotherapy followed by Gazyva monotherapy in patients with stage II bulky, III, or IV follicular lymphoma (FL); and combined with (Bendeka) bendamustine followed by Gazyva monotherapy for FL in adults who did not respond to a rituximab-containing regimen, or whose FL returned.

What are experts saying?

Levi Garraway, Roche’s chief medical officer and head of Global Product Development, said the filing acceptance represents progress toward a new treatment option that could improve disease control and reduce reliance on long-term steroid use.

Albert T. Roy, president and CEO of the Lupus Research Alliance, highlighted the potential for the therapy to help manage symptoms, increase remission rates, and reduce the frequency of debilitating flares.

What is next for Gazyva/Gazyvaro?

In addition to the FDA submission, ALLEGORY data have also been filed with the European Medicines Agency. The therapy is already approved in the US and EU for lupus nephritis and in more than 100 countries for certain hematological cancers.

ALLEGORY is one of four positive Phase III trials evaluating Gazyva/Gazyvaro in immune-mediated diseases, underscoring its broader potential across immunology indications.

If approved for SLE, Gazyva/Gazyvaro could expand its role beyond kidney involvement to address systemic disease activity more broadly.

References

1. A Study to Evaluate the Efficacy and Safety of Obinutuzumab in Participants With Systemic Lupus Erythematosus (ALLEGORY). National Library of Medicine. ClinicalTrials.gov. https://clinicaltrials.gov/study/NCT04963296?term=ALLEGORY&rank=1
   
2. Furie, RA; Dall'Era, M; Vital EM; et al. (2026 Mar 6). Efficacy and Safety of Obinutuzumab in Active Systemic Lupus Erythematosus. National Library of Medicine. PubMed. https://pubmed.ncbi.nlm.nih.gov/41789864/#:~:text=At%20week%2052%2C%20an%20SRI,%C2%A9%202026%20Massachusetts%20Medical%20Society.